A possible role for B cells in COVID-19? Lesson from pat

Journal of Allergy and Clinical Immunology
146, 211-213.e4
DOI: 10.1016/j.jaci.2020.04.013

Citation Report

#	Article	IF	Citations
1	Management of the patient with allergic and immunological disorders in the pandemic COVID-19 era. Clinical and Molecular Allergy, 2020, 18, 18.	0.8	8
2	Mild SARS-CoV-2 Infection After Gene Therapy in a Child With Wiskott-Aldrich Syndrome: A Case Report. Frontiers in Immunology, 2020, 11, 603428.	2.2	8
3	Whatâ€™s Sex Got to Do With COVID-19? Gender-Based Differences in the Host Immune Response to Coronaviruses. Frontiers in Immunology, 2020, 11, 2147.	2.2	131
4	Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3594-3596.e3.	2.0	72
5	Rapid recovery of a SARS-CoV-2â€“infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2793-2795.	2.0	74
6	COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clinical and Experimental Immunology, 2020, 202, 149-161.	1.1	155
7	High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects. Frontiers in Immunology, 2020, 11, 1660.	2.2	48
8	Clinical Outcomes of COVID-19 Patients with Pre-existing, Compromised Immune Systems: A Review of Case Reports. International Journal of Medical Sciences, 2020, 17, 2974-2986.	1.1	16
9	HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients. Frontiers in Immunology, 2020, 11, 607918.	2.2	37
10	Immunological basis of virusâ€host interaction in COVIDâ€19. Pediatric Allergy and Immunology, 2020, 31, 75-78.	1.1	9
11	SARS-CoV-2 and interferon blockade. Molecular Medicine, 2020, 26, 103.	1.9	3
12	Increased ILâ€10â€producing regulatory T cells are characteristic of severe cases of COVIDâ€19. Clinical and Translational Immunology, 2020, 9, e1204.	1.7	59
13	Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: â€˜Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et alâ€™ by Benucciet al. Annals of the Rheumatic Diseases, 2022, 81, e185-e185.	0.5	5
14	Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination. CNS Drugs, 2020, 34, 879-896.	2.7	80
15	Establishing a Unified COVID-19 â€œImmunomeâ€: Integrating Coronavirus Pathogenesis and Host Immunopathology. Frontiers in Immunology, 2020, 11, 1642.	2.2	11
16	Severe Acute Respiratory Syndrome Coronavirus 2 and Coronavirus Disease 2019: A Clinical Overview and Primer. Biopreservation and Biobanking, 2020, 18, 492-502.	0.5	9
17	Primary Immunodeficiency Diseases in COVID-19 Pandemic: A Predisposing or Protective Factor?. American Journal of the Medical Sciences, 2020, 360, 740-741.	0.4	77
18	Case Report: Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19. Frontiers in Immunology, 2020, 11, 596761.	2.2	45

#	Article	IF	Citations
19	Immune Correlates of COVID-19 Control. Frontiers in Immunology, 2020, 11, 569611.	2.2	21
20	Reducing immunosuppressant use in patients with chronic inflammation during the COVIDâ€19 pandemic: Risks versus benefits. Journal of Cutaneous Immunology and Allergy, 2020, 3, 120-121.	0.2	0
21	Antibody Response to Severe Acute Respiratory Syndromeâ€•Corona Virus 2, Diagnostic and Therapeutic Implications. Hepatology Communications, 2020, 4, 1731-1743.	2.0	6
22	Role of Host Immune and Inflammatory Responses in COVID-19 Cases with Underlying Primary Immunodeficiency: A Review. Journal of Interferon and Cytokine Research, 2020, 40, 549-554.	0.5	40
23	SARS-CoV-2 and Viral Sepsis: Immune Dysfunction and Implications in Kidney Failure. Journal of Clinical Medicine, 2020, 9, 4057.	1.0	31
24	Lymphocyte Changes in Severe COVID-19: Delayed Over-Activation of STING?. Frontiers in Immunology, 2020, 11, 607069.	2.2	38
25	Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nature Communications, 2020, 11, 6385.	5.8	103
26	COVIDâ€19 therapy with mesenchymal stromal cells (MSC) and convalescent plasma must consider exosome involvement: Do the exosomes in convalescent plasma antagonize the weak immune antibodies?. Journal of Extracellular Vesicles, 2020, 10, e12004.	5.5	43
27	Maturation of T and B Lymphocytes in the Assessment of the Immune Status in COVID-19 Patients. Cells, 2020, 9, 2615.	1.8	13
28	Obesity and immune status in children. Current Opinion in Pediatrics, 2020, 32, 805-815.	1.0	33
29	Clinical Observation of COVID-19 in a Patient With an Acquired Humoral Deficiency Secondary to Chemotherapeutic Agents. Allergy and Rhinology, 2020, 11, 215265672097876.	0.7	3
30	ADE and hyperinflammation in SARS-CoV2 infection- comparison with dengue hemorrhagic fever and feline infectious peritonitis. Cytokine, 2020, 136, 155256.	1.4	26
31	The first, holistic immunological model of COVIDâ€19: Implications for prevention, diagnosis, and public health measures. Pediatric Allergy and Immunology, 2020, 31, 454-470.	1.1	156
32	Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19. Vaccines, 2020, 8, 224.	2.1	47
33	Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain. Multiple Sclerosis and Related Disorders, 2020, 42, 102185.	0.9	118
34	B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Multiple Sclerosis and Related Disorders, 2020, 43, 102195.	0.9	123
35	Neutralizing antibodies mediate virus-immune pathology of COVID-19. Medical Hypotheses, 2020, 143, 109884.	0.8	16
36	Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19. Frontiers in Immunology, 2020, 11, 1606.	2.2	43

#	Article	IF	Citations
37	Consensus statement of the Italian society of pediatric allergy and immunology for the pragmatic management of children and adolescents with allergic or immunological diseases during the COVID-19 pandemic. Italian Journal of Pediatrics, 2020, 46, 84.	1.0	69
38	Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab. Multiple Sclerosis and Related Disorders, 2020, 44, 102297.	0.9	25
40	Neurological immunotherapy in the era of COVID-19 â€" looking for consensus in the literature. Nature Reviews Neurology, 2020, 16, 493-505.	4.9	57
41	Is COVID-19 a New Hematologic Disease?. Stem Cell Reviews and Reports, 2021, 17, 4-8.	1.7	82
42	COVID-19 in Immunocompromised Hosts: What We Know So Far. Clinical Infectious Diseases, 2021, 72, 340-350.	2.9	389
43	Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Annals of the Rheumatic Diseases, 2021, 80, e67-e67.	0.5	109
44	A review on how to do hematology consults during COVID-19 pandemic. Blood Reviews, 2021, 47, 100777.	2.8	20
45	Continuous extracorporeal treatments in a dialysis patient with COVID-19. CEN Case Reports, 2021, 10, 172-177.	0.5	7
46	Severe SARS-CoV-2 disease in the context of a NF-Î¹B2 loss-of-function pathogenic variant. Journal of Allergy and Clinical Immunology, 2021, 147, 532-544.e1.	1.5	25
47	Coronavirus disease 2019 in patients with inborn errors of immunity: An international study. Journal of Allergy and Clinical Immunology, 2021, 147, 520-531.	1.5	278
48	Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 490-493.e2.	2.0	72
49	T cell immunity to SARS-CoV-2 following natural infection and vaccination. Biochemical and Biophysical Research Communications, 2021, 538, 211-217.	1.0	88
50	Non-neutralizing antibodies and limitations of serologic testing for severe acute respiratory syndrome coronavirus 2 in patients receiving immunoglobulin replacement products. Annals of Allergy, Asthma and Immunology, 2021, 126, 206-207.	0.5	5
51	Human Inborn Errors of Immunity (HIEI): predominantly antibody deficiencies (PADs): if you suspect it, you can detect it. Jornal De Pediatria, 2021, 97, S67-S74.	0.9	4
52	Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency. Journal of Clinical Immunology, 2021, 41, 345-355.	2.0	97
53	Minor Clinical Impact of COVID-19 Pandemic on Patients With Primary Immunodeficiency in Israel. Frontiers in Immunology, 2020, 11, 614086.	2.2	81
54	Fatal SARS-CoV-2 infection in a male patient with Good's syndrome. Clinical Immunology, 2021, 223, 108644.	1.4	15
55	Exploring the multifocal therapeutic approaches in COVID-19: A ray of hope. International Immunopharmacology, 2021, 90, 107156.	1.7	5

#	Article	IF	Citations
56	Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy. Journal of Clinical Immunology, 2021, 41, 356-361.	2.0	35
57	The Impact of Immunosuppression and Autoimmune Disease on Severe Outcomes in Patients Hospitalized with COVID-19. Journal of Clinical Immunology, 2021, 41, 315-323.	2.0	16
58	Multidimensional Proteomic Approach of Endothelial Progenitors Demonstrate Expression of KDR Restricted to CD19 Cells. Stem Cell Reviews and Reports, 2021, 17, 639-651.	1.7	18
59	COVID-19 infection in 10 common variable immunodeficiency patients in New York City. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 504-507.e1.	2.0	31
60	Zoonotic coronavirus epidemics. Annals of Allergy, Asthma and Immunology, 2021, 126, 321-337.	0.5	8
61	Peculiar immunophenotypic signature in MISâ€Câ€affected children. Pediatric Allergy and Immunology, 2021, 32, 801-804.	1.1	4
62	COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience. Journal of Allergy and Clinical Immunology, 2021, 147, 870-875.e1.	1.5	188
63	B cell analysis in SARS-CoV-2 versus malaria: Increased frequencies of plasmablasts and atypical memory B cells in COVID-19. Journal of Leukocyte Biology, 2021, 109, 77-90.	1.5	46
64	SARS-CoV-2 positive virus culture 7 weeks after onset of COVID-19 in an immunocompromised patient suffering from X chromosome-linked agammaglobulinemia. Journal of Infection, 2021, 82, 414-451.	1.7	17
65	Recovery from COVID-19 in a Child with Chronic Granulomatous Disease and T Cell Lymphopenia. Journal of Clinical Immunology, 2021, 41, 23-25.	2.0	7
66	A fatal case of coronavirus disease 2019 in a patient with common variable immunodeficiency. Annals of Allergy, Asthma and Immunology, 2021, 126, 90-92.	0.5	34
67	Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T-cell memory formation after mild COVID-19 infection. ELife, 2021, 10, .	2.8	103
68	Immune determinants of COVID-19 disease presentation and severity. Nature Medicine, 2021, 27, 28-33.	15.2	490
69	Case Report: B Lymphocyte Disorders Under COVID-19 Inflammatory Pressure. Frontiers in Oncology, 2020, 10, 582901.	1.3	2
71	COVID-19, rheumatic diseases and immune dysregulationâ€"a perspective. Clinical Rheumatology, 2021, 40, 433-442.	1.0	11
72	The Impact of the SARS-CoV-2 Pandemic in PID Patients Receiving Ig Replacement Therapy. Journal of Clinical Immunology, 2021, 41, 733-737.	2.0	1
73	Rapid clinical recovery of a SARS-CoV-2 infected common variable immunodeficiency patient following the infusion of COVID-19 convalescent plasma. Allergy, Asthma and Clinical Immunology, 2021, 17, 14.	0.9	22
74	Update on Infections in Primary Antibody Deficiencies. Frontiers in Immunology, 2021, 12, 634181.	2.2	20

#	Article	IF	Citations
75	SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. Vaccines, 2021, 9, 147.	2.1	175
76	COVID-19 HastalarÄ±nda Potansiyel Ä°mmÃ¼nolojik Tedaviler. Duzce Universitesi Tip FakÃ¼ltesi Dergisi, 2021, 23, 1-9.	0.3	2
77	A Patient with X-Linked Agammaglobulinemia and COVID-19 Infection Treated with Remdesivir and Convalescent Plasma. Journal of Clinical Immunology, 2021, 41, 923-925.	2.0	25
78	The Clinical Course of COVID-19 Pneumonia in a 19-Year-Old Man on Intravenous Immunoglobulin Replacement Therapy for X-Linked Agammaglobulinemia. American Journal of Case Reports, 2021, 22, e929447.	0.3	12
79	Interindividual immunogenic variants: Susceptibility to coronavirus, respiratory syncytial virus and influenza virus. Reviews in Medical Virology, 2021, 31, e2234.	3.9	12
80	SARS-CoV-2 infection associated with hepatitis in an infant with X-linked severe combined immunodeficiency. Clinical Immunology, 2021, 224, 108662.	1.4	20
81	Drugs used in the treatment of multiple sclerosis during COVID-19 pandemic: a critical viewpoint. Current Neuropharmacology, 2021, 19, .	1.4	5
82	Convalescent plasma and hyperimmune globulin therapy in COVID-19. Expert Review of Clinical Immunology, 2021, 17, 309-315.	1.3	10
83	The course and outcomes of COVID-19 in patients with ANCA-associated systemic vasculitis, receiving biological therapy (Rituximab, Mepolizumab): The results of the first 8 months of the pandemic. Nauchno-Prakticheskaya Revmatologiya, 2021, 59, 37-46.	0.2	5
84	Impact of COVID-19 Pandemic on Patients with Immune Thrombocytopaenia. Medicina (Lithuania), 2021, 57, 219.	0.8	1
85	COVID-19 Vaccination in Patients With Multiple Sclerosis on Disease-Modifying Therapy. Neurology: Clinical Practice, 2021, 11, 358-361.	0.8	14
86	IgA Antibodies and IgA Deficiency in SARS-CoV-2 Infection. Frontiers in Cellular and Infection Microbiology, 2021, 11, 655896.	1.8	55
87	Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2904-2906.e2.	2.0	56
88	Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery. Frontiers in Immunology, 2021, 12, 613502.	2.2	13
89	The Use of Brutonâ€™s Tyrosine Kinase Inhibitors to Treat Allergic Disorders. Current Treatment Options in Allergy, 2021, 8, 261-273.	0.9	15
90	Immune Profile in Patients With COVID-19: Lymphocytes Exhaustion Markers in Relationship to Clinical Outcome. Frontiers in Cellular and Infection Microbiology, 2021, 11, 646688.	1.8	47
91	Dual Nature of Type I Interferons in SARS-CoV-2-Induced Inflammation. Trends in Immunology, 2021, 42, 312-322.	2.9	86
92	Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations. Expert Review of Vaccines, 2022, 21, 877-884.	2.0	24

#	Article	IF	Citations
93	Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency. Journal of Clinical Immunology, 2021, 41, 1146-1153.	2.0	45
94	Research Progress of Mesenchymal Stem Cell Therapy for Severe COVID-19. Stem Cells and Development, 2021, 30, 459-472.	1.1	2
96	COVID-19 vaccination for patients with primary immunodeficiency. LymphoSign Journal, 2021, 8, 37-45.	0.1	8
97	The TNFRSF13C H159Y Variant Is Associated with Severe COVID-19: A Retrospective Study of 500 Patients from Southern Italy. Genes, 2021, 12, 881.	1.0	12
98	Early and High SARS-CoV-2 Neutralizing Antibodies Are Associated with Severity in COVID-19 Patients from India. American Journal of Tropical Medicine and Hygiene, 2021, , .	0.6	9
99	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. Microorganisms, 2021, 9, 1389.	1.6	4
100	Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 701752.	2.2	17
101	Multi-dimensional and longitudinal systems profiling reveals predictive pattern of severe COVID-19. IScience, 2021, 24, 102752.	1.9	9
102	How Children Are Protected From COVID-19? A Historical, Clinical, and Pathophysiological Approach to Address COVID-19 Susceptibility. Frontiers in Immunology, 2021, 12, 646894.	2.2	13
103	The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respiratory Medicine,the, 2021, 9, 622-642.	5.2	371
104	Targeting Brutonâ€™s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies. Frontiers in Cell and Developmental Biology, 2021, 9, 668131.	1.8	26
105	Rapid, simplified whole blood-based multiparameter assay to quantify and phenotype SARS-CoV-2-specific T-cells. European Respiratory Journal, 2022, 59, 2100285.	3.1	14
107	Common Variable Immunodeficiency Disorders, T-Cell Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic COVID-19. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3575-3583.	2.0	41
108	Outcome of SARS-CoV-2 Infection in 121 Patients with Inborn Errors of Immunity: A Cross-Sectional Study. Journal of Clinical Immunology, 2021, 41, 1479-1489.	2.0	56
109	COVID-19 in the Context of Inborn Errors of Immunity: a Case Series of 31 Patients from Mexico. Journal of Clinical Immunology, 2021, 41, 1463-1478.	2.0	40
110	Differential alterations in peripheral lymphocyte subsets in COVID-19 patients: upregulation of double-positive and double-negative T cells. Multidisciplinary Respiratory Medicine, 2021, 16, 758.	0.6	8
111	Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-Î². Journal of Clinical Immunology, 2021, 41, 1425-1442.	2.0	39
112	Agammaglobulinemia: from X-linked to Autosomal Forms of Disease. Clinical Reviews in Allergy and Immunology, 2022, 63, 22-35.	2.9	19

#	Article	IF	Citations
113	Antibody-independent functions of B cells during viral infections. PLoS Pathogens, 2021, 17, e1009708.	2.1	37
114	Anti-inflammatory Therapy by Cholinergic and Purinergic Modulation in Multiple Sclerosis Associated with SARS-CoV-2 Infection. Molecular Neurobiology, 2021, 58, 5090-5111.	1.9	10
115	Reactive T Cells in Convalescent COVID-19 Patients With Negative SARS-CoV-2 Antibody Serology. Frontiers in Immunology, 2021, 12, 687449.	2.2	26
116	TBK1 and TNFRSF13B mutations and an autoinflammatory disease in a child with lethal COVID-19. Npj Genomic Medicine, 2021, 6, 55.	1.7	38
117	Subacute SARS-CoV-2 replication can be controlled in the absence of CD8+ÂT cells inÂcynomolgusÂmacaques. PLoS Pathogens, 2021, 17, e1009668.	2.1	9
118	COVID-19 in Patients with Primary Immunodeficiency. Journal of Clinical Immunology, 2021, 41, 1515-1522.	2.0	38
119	Immunity to SARSâ€CoVâ€2 induced by infection or vaccination. Journal of Internal Medicine, 2022, 291, 32-50.	2.7	97
120	Self-Limited COVID-19 in a Patient with Artemis Hypomorphic SCID. Journal of Clinical Immunology, 2021, 41, 1745-1747.	2.0	7
121	Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Annals of the Rheumatic Diseases, 2021, 80, 1322-1329.	0.5	188
122	The clinical spectrum of SARS-CoV-2 infection in Gaucher disease: Effect of both a pandemic and a rare disease that disrupts the immune system. Molecular Genetics and Metabolism, 2022, 135, 115-121.	0.5	3
123	Low morbidity in Danish patients with common variable immunodeficiency disorder infected with severe acute respiratory syndrome coronavirus 2. Infectious Diseases, 2021, 53, 1-6.	1.4	13
124	Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges. Frontiers in Microbiology, 2021, 12, 637554.	1.5	8
125	Expert Perspectives on COVID-19 Vaccination for People Living with Multiple Sclerosis. Neurology and Therapy, 2021, 10, 415-425.	1.4	5
126	Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease. PLoS ONE, 2021, 16, e0255335.	1.1	48
127	The protective immunity induced by SARS-CoV-2 infection and vaccination: a critical appraisal. Exploration of Immunology, 2021, , 199-225.	1.7	5
128	Prior COVID-19 protects against reinfection, even in the absence of detectable antibodies. Journal of Infection, 2021, 83, 237-279.	1.7	29
129	COVID-19 post-vaccination recommendations for primary immunodeficiency. LymphoSign Journal, 0, , 1-6.	0.1	2
130	The sex-related discrepancy in laboratory parameters of severe COVID-19 patients with diabetes: A retrospective cohort study. Primary Care Diabetes, 2021, 15, 713-718.	0.9	5

#	Article	IF	Citations
131	Successful treatment of COVIDâ€19 infection with convalescent plasma in Bâ€cellâ€depleted patients may promote cellular immunity. European Journal of Immunology, 2021, 51, 2478-2484.	1.6	8
132	COVID-19 in children and young adults with moderate/severe inborn errors of immunity in a high burden area in pre-vaccine era. Clinical Immunology, 2021, 230, 108821.	1.4	16
133	B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19). Nauchno-Prakticheskaya Revmatologiya, 2021, 59, 384-393.	0.2	12
134	SARS-CoV-2 Infection in the Immunodeficient Host: Necessary and Dispensable Immune Pathways. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3237-3248.	2.0	4
135	Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies. Biomedicines, 2021, 9, 1163.	1.4	18
136	Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab. Blood Cancer Journal, 2021, 11, 151.	2.8	32
137	Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity. Journal of Allergy and Clinical Immunology, 2021, 148, 739-749.	1.5	151
138	Seroconversion after coronavirus disease 2019 vaccination in patients with immune deficiency. Annals of Allergy, Asthma and Immunology, 2021, 127, 383-384.	0.5	30
139	COVID-19 in complex common variable immunodeficiency patients affected by lung diseases. Current Opinion in Allergy and Clinical Immunology, 2021, 21, 535-544.	1.1	16
140	The immune response to SARS-CoV-2 and COVID-19 immunopathology â€“ Current perspectives. Pulmonology, 2021, 27, 423-437.	1.0	118
141	SARS-CoV-2 infection causes immunodeficiency in recovered patients by downregulating CD19 expression in B cells via enhancing B-cell metabolism. Signal Transduction and Targeted Therapy, 2021, 6, 345.	7.1	30
142	An association between immune status and chest CT scores in COVIDâ€19 patients. International Journal of Clinical Practice, 2021, 75, e14767.	0.8	3
143	Prevalence and Course of SARS-CoV-2 Infection among Immunocompromised Children Hospitalised in the Tertiary Referral Hospital in Poland. Journal of Clinical Medicine, 2021, 10, 4556.	1.0	3
144	Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity. Journal of Allergy and Clinical Immunology, 2021, 148, 1192-1197.	1.5	67
145	Clinical characteristics of COVIDâ€19 in children and young adolescents with inborn errors of immunity. Pediatric Allergy and Immunology, 2022, 33, .	1.1	5
146	Mechanisms underlying host defense and disease pathology in response to severe acute respiratory syndrome (SARS)-CoV2 infection: insights from inborn errors of immunity. Current Opinion in Allergy and Clinical Immunology, 2021, 21, 515-524.	1.1	19
147	Relationship between Selective IgA Deficiency and COVID-19 Prognosis. Japanese Journal of Infectious Diseases, 2022, 75, 228-233.	0.5	12
148	Coronavirus disease 2019 in patients with inborn errors of immunity: lessons learned. Current Opinion in Pediatrics, 2021, 33, 648-656.	1.0	42

#	Article	IF	Citations
149	Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	9
150	X-Linked Agammaglobulinemia and COVID-19: Two Case Reports and Review of Literature. Pediatric, Allergy, Immunology, and Pulmonology, 2021, 34, 115-118.	0.3	10
151	Common variable immunodeficiency (CVID) with granulomatous interstitial lung disease (GLILD) and SARS COVID-19 infection: case report and review of literature. Allergy, Asthma and Clinical Immunology, 2021, 17, 98.	0.9	4
152	COVID-19 and X-linked agammaglobulinemia (XLA) â€“ insights from a monogenic antibody deficiency. Current Opinion in Allergy and Clinical Immunology, 2021, 21, 525-534.	1.1	22
153	COVID-19 in a Leukemic Child. Malaysian Journal of Paediatrics and Child Health, 2021, 27, .	0.1	0
154	Clinical management of patients with primary immunodeficiencies during the COVID-19 pandemic. Expert Review of Clinical Immunology, 2021, 17, 163-168.	1.3	15
159	From infections to autoimmunity: Diagnostic challenges in common variable immunodeficiency. World Journal of Clinical Cases, 2020, 8, 3942-3955.	0.3	9
160	Understanding the immunopathogenesis of COVID-19: Its implication for therapeutic strategy. World Journal of Clinical Cases, 2020, 8, 5835-5843.	0.3	11
161	In silico immune infiltration profiling combined with functional enrichment analysis reveals a potential role for naÃ¯ve B cells as a trigger for severe immune responses in the lungs of COVID-19 patients. PLoS ONE, 2020, 15, e0242900.	1.1	13
162	Atypical course of COVID-19 in patient with Bruton agammaglobulinemia. Journal of Infection in Developing Countries, 2020, 14, 1248-1251.	0.5	23
163	Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives (Review). International Journal of Molecular Medicine, 2020, 46, 903-912.	1.8	73
164	Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 353-367.	0.2	33
165	Covid-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab). Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 456-462.	0.2	7
166	Brutonâ€™s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease. Drugs, 2021, 81, 1605-1626.	4.9	29
167	Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies. Frontiers in Immunology, 2021, 12, 727850.	2.2	69
168	SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does their Best. Journal of Clinical Immunology, 2021, 41, 1709-1722.	2.0	68
169	Potential therapeutic approach of intravenous immunoglobulin against COVID-19. Allergy, Asthma and Clinical Immunology, 2021, 17, 105.	0.9	9
170	Cardiovascular diseases in combination with SARS-CoV-2 viral infection: cours and forecast. , 2021, 17, 97-105.	0.0	3

#	Article	IF	Citations
171	COVID-19 Advanced Care. Journal of Personalized Medicine, 2021, 11, 1082.	1.1	1
172	Spike Glycoprotein Is Central to Coronavirus Pathogenesis-Parallel Between m-CoV and SARS-CoV-2. Annals of Neurosciences, 2021, 28, 201-218.	0.9	7
173	Virus-bacterial association of SARS-CoV-2 with mycoplasma as one of the possible causes of severe forms of COVID-19. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2020, , 143-151.	0.1	1
174	B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies. Cells, 2021, 10, 2915.	1.8	35
175	Expanding the toolbox to combat a pandemic. Blood, 2020, 136, 2847-2848.	0.6	0
176	COVID-19 grave: entenda o papel da imunidade, do endotÃ©lio e da coagulaÃ§Ã£o na prÃ¡tica clÃnica. Jornal Vascular Brasileiro, 2020, 19, e20200131.	0.1	10
177	Primary immunodeficiency in the SARS-CoV-2 pandemic. Alergologia, 2020, 4, 166.	0.1	0
178	Sub-optimal Humoral immunity in SARS CoV-2 infection and viral variant generation. Clinics in Laboratory Medicine, 2021, 42, 75-84.	0.7	1
179	Transient increased immunoglobulin levels in a hyper-IgM syndrome patient with COVID-19 infection. Allergologia Et Immunopathologia, 2021, 49, 63-66.	1.0	1
180	T helper type (Th1/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: From cytokines produced to immune responses. Transplant Immunology, 2022, 70, 101495.	0.6	58
181	Treatment of chronic or relapsing COVID-19 in immunodeficiency. Journal of Allergy and Clinical Immunology, 2022, 149, 557-561.e1.	1.5	56
182	A Pilot Study for the Evaluation of an Interferon Gamma Release Assay (IGRA) To Measure T-Cell Immune Responses after SARS-CoV-2 Infection or Vaccination in a Unique Cloistered Cohort. Journal of Clinical Microbiology, 2022, 60, jcm0219921.	1.8	28
183	Common Variable Immunodeficiency Disorders as a Model for Assessing COVID-19 Vaccine Responses in Immunocompromised Patients. Frontiers in Immunology, 2021, 12, 798389.	2.2	6
184	Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody therapy administration: an Italian inter-society consensus statement. Italian Journal of Pediatrics, 2022, 48, 7.	1.0	9
185	T-cell responses to SARS-CoV-2 in healthy controls and primary immunodeficiency patients. Clinical and Experimental Immunology, 2022, 207, 336-339.	1.1	4
186	Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases. RMD Open, 2022, 8, e001898.	1.8	36
187	The Immune Response to SARS-CoV-2 Vaccination: Insights Learned From Adult Patients With Common Variable Immune Deficiency. Frontiers in Immunology, 2021, 12, 815404.	2.2	26
188	Memory B cells and serum immunoglobulins are associated with disease severity and mortality in patients with COVID-19. Postgraduate Medical Journal, 2022, 98, 765-771.	0.9	14

#	Article	IF	Citations
189	Advances in clinical outcomes: What we have learned during the COVID-19 pandemic. Journal of Allergy and Clinical Immunology, 2022, 149, 569-578.	1.5	3
190	COVID-19 in the Immunocompromised Host, Including People with Human Immunodeficiency Virus. Infectious Disease Clinics of North America, 2022, 36, 397-421.	1.9	7
191	Immune response to SARS-CoV-2 variants: A focus on severity, susceptibility, and preexisting immunity. Journal of Infection and Public Health, 2022, 15, 277-288.	1.9	21
192	Development of SARS-CoV2 humoral response including neutralizing antibodies is not sufficient to protect patients against fatal infection. Scientific Reports, 2022, 12, 2077.	1.6	8
193	Immunogenicity of COVID-19 mRNA vaccines in immunocompromised patients: a systematic review and meta-analysis. European Journal of Medical Research, 2022, 27, 23.	0.9	36
194	The (apparent) antibody paradox in COVID-19. Expert Review of Clinical Immunology, 2022, 18, 335-345.	1.3	9
195	Impact of Hypogammaglobulinemia on the Course of COVID-19 in a Non-Intensive Care Setting: A Single-Center Retrospective Cohort Study. Frontiers in Immunology, 2022, 13, 842643.	2.2	6
196	Activated CD8+CD38+ Cells Are Associated With Worse Clinical Outcome in Hospitalized COVID-19 Patients. Frontiers in Immunology, 2022, 13, 861666.	2.2	8
197	SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity. Frontiers in Immunology, 2022, 13, 840126.	2.2	20
198	The Causeâ€“Effect Dilemma of Hematologic Changes in COVID-19: One Year after the Start of the Pandemic. Hematology Reports, 2022, 14, 95-102.	0.3	2
199	Immunodeficiency: A Protective Factor for COVID-19?. Cureus, 2022, 14, e23094.	0.2	1
200	Do reduced numbers of plasmacytoid dendritic cells contribute to the aggressive clinical course of COVIDâ€19 in chronic lymphocytic leukaemia?. Scandinavian Journal of Immunology, 2022, 95, e13153.	1.3	5
201	SARS-CoV-2-Specific and Functional Cytotoxic CD8 Cells in Primary Antibody Deficiency: Natural Infection and Response to Vaccine. Journal of Clinical Immunology, 2022, 42, 914-922.	2.0	16
202	Response to Severe Acute Respiratory Syndrome Coronavirus 2 Initial Series and Additional Dose Vaccine in Patients With Predominant Antibody Deficiency. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1622-1634.e4.	2.0	12
203	Monoclonal anti-CD20 antibodies in lymphomas therapy during the COVID-19 pandemic: pro and contra. Oncogematologiya, 2022, 17, 95-106.	0.1	0
214	The Outcome of COVID-19 in Patients with a History of Taking Rituximab: A Narrative Review. Iranian Journal of Medical Sciences, 2021, 46, 411-419.	0.3	2
215	The Effect of COVID-19 Pandemic on Patients with Primary Immunodeficiency: A Cohort Study.. Iranian Journal of Medical Sciences, 2022, 47, 162-166.	0.3	3
216	Associations and Diseaseâ€“Disease Interactions of COVID-19 with Congenital and Genetic Disorders: A Comprehensive Review. Viruses, 2022, 14, 910.	1.5	6

#	Article	IF	Citations
217	Milder COVID-19 in children with inborn errors of immunity. Pediatric Hematology Oncology Journal, 2022, 7, 90-91.	0.1	2
218	Severe COVID-19 is a T cell immune dysregulatory disorder triggered by SARS-CoV-2. Expert Review of Clinical Immunology, 2022, 18, 557-565.	1.3	10
219	COVID-19 outcomes in immunocompromised individuals: seroconversion and vaccine effectiveness. LymphoSign Journal, 0, , .	0.1	1
220	Immunizing the imperfect immune system. Annals of Allergy, Asthma and Immunology, 2022, 129, 562-571.e1.	0.5	16
221	SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients?. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 2267-2273.	2.0	10
222	SARS-CoV-2 the ASIA virus (Autoimmune/autoinflammatory Syndrome Induced by Adjuvants), the risk of infertility and vaccine hesitancy. Expert Review of Vaccines, 2022, 21, 1177-1184.	2.0	6
223	The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. Frontiers in Immunology, 0, 13, .	2.2	28
224	COVID-19 disease and autoimmune disorders: A mutual pathway. World Journal of Methodology, 2022, 12, 200-223.	1.1	12
225	Ocular Manifestations of COVID-19 in a Patient with ANCAAssociated Vasculitis Treated with Rituximab. A Case Report. Oftalmologiya, 2022, 19, 452-457.	0.2	1
226	Molecular mechanisms involved in pathogenicity of SARS-CoV-2: Immune evasion and implications for therapeutic strategies. Biomedicine and Pharmacotherapy, 2022, 153, 113368.	2.5	6
227	Clinical implications of host genetic variation and susceptibility to severe or critical COVID-19. Genome Medicine, 2022, 14, .	3.6	28
228	Response to mRNA COVID-19 vaccination in three XLA patients. Vaccine, 2022, 40, 5299-5301.	1.7	2
229	COVID-19 and Inborn Errors of Immunity. Physiology, 2022, 37, 290-301.	1.6	14
230	COVID-19 infection and vaccination in immunodeficiency. Clinical and Experimental Immunology, 2022, 209, 259-261.	1.1	2
231	Vaccination in patients with kidney failure: lessons from COVID-19. Nature Reviews Nephrology, 2022, 18, 708-723.	4.1	46
232	SARS-CoV-2 infection in pediatric population before and during the Delta (B.1.617.2) and Omicron (B.1.1.529) variants era. Virology Journal, 2022, 19, .	1.4	41
233	Common Variable Immunodeficiency: Predisposing or Protective Factor for Severe Complications of COVID-19?. Acta Clinica Croatica, 2022, 61, .	0.1	0
234	Goodâ€™s syndrome and COVID-19: case report and literature review. Mediastinum, 0, 7, 5-5.	0.6	3

#	Article	IF	Citations
235	Genetic and immunologic evaluation of children with inborn errors of immunity and severe or critical COVID-19. Journal of Allergy and Clinical Immunology, 2022, 150, 1059-1073.	1.5	22
236	COVID-19 vs. Cancer Immunosurveillance: A Game of Thrones within an Inflamed Microenviroment. Cancers, 2022, 14, 4330.	1.7	4
237	Serum biomarkers associated with SARS-CoV-2 severity. Scientific Reports, 2022, 12, .	1.6	12
238	Outcome of SARS-CoV-2 infection among patients with common variable immunodeficiency and a matched control group: A Danish nationwide cohort study. Frontiers in Immunology, 0, 13, .	2.2	10
239	COVID-19 in unvaccinated patients with inborn errors of immunityâ€"polish experience. Frontiers in Immunology, 0, 13, .	2.2	6
240	Dynamics of immune system parameters in development of SARS-CoV-2-specific immunity in a patient with common variable immune deficiency. Russian Journal of Immunology: RJI: Official Journal of Russian Society of Immunology, 2022, 25, 529-534.	0.2	0
241	Critical role of diagnostic SARS-CoV-2 T cell assays for immunodeficient patients. Journal of Clinical Pathology, 2022, 75, 793-797.	1.0	2
242	Immune response induced by novel coronavirus infection. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	8
243	Selective IgA Deficiency May Be an Underrecognized Risk Factor for Severe COVID-19. Journal of Allergy and Clinical Immunology: in Practice, 2023, 11, 181-186.	2.0	4
244	Acquired B-cell deficiency secondary to B-cell-depleting therapies. Journal of Immunological Methods, 2022, 511, 113385.	0.6	4
245	SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies. Seminars in Hematology, 2022, 59, 192-197.	1.8	5
246	Confirmed SARS-CoV-2 Reinfection After 1 Year in a Patient with X-linked Agammaglobulinaemia. , 2022, 1, 35.		0
247	Coronavirus Disease-2019 in the Immunocompromised Host. Clinics in Chest Medicine, 2023, 44, 395-406.	0.8	5
248	Case report: Evolution of pulmonary manifestations and virological markers in critical COVID-19 infection in Brutonâ€™s agammaglobulinemia. Frontiers in Immunology, 0, 13, .	2.2	3
249	How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?. Stem Cell Reviews and Reports, 0, , .	1.7	2
250	Autoimmunity and Immunodeficiency in Severe SARS-CoV-2 Infection and Prolonged COVID-19. Current Issues in Molecular Biology, 2023, 45, 33-50.	1.0	14
251	Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity. Journal of Allergy and Clinical Immunology, 2023, 151, 818-831.	1.5	13
252	ProlongedSARS-CoV-2 Infection With Common Features in Two Patients Receiving Anti-CD20 Therapy. In Vivo, 2023, 37, 461-467.	0.6	2

#	Article	IF	Citations
253	Exploring the Role of Immune System and Inflammatory Cytokines in SARS-CoV-2 Induced Lung Disease: A Narrative Review. Biology, 2023, 12, 177.	1.3	11
254	Acute and long-term immune responses to SARS-CoV-2 infection in unvaccinated children and young adults with inborn errors of immunity. Frontiers in Immunology, 0, 14, .	2.2	1
255	Innate and Adaptive Immunity during SARS-CoV-2 Infection: Biomolecular Cellular Markers and Mechanisms. Vaccines, 2023, 11, 408.	2.1	14
256	Immunity in SARS-CoV-2 Infection: Clarity or Mystery? A Broader Perspective in the Third Year of a Worldwide Pandemic. Archivum Immunologiae Et Therapiae Experimentalis, 2023, 71, .	1.0	4
261	Editorial: Advances in primary immunodeficiencies (inborn errors of immunity) in Central-Eastern Europe, volume II. Frontiers in Immunology, 0, 14, .	2.2	0